Welcome to our dedicated page for Hims & Hers Health SEC filings (Ticker: HIMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Hims & Hers Health, Inc. filings document the regulatory record for a public consumer telehealth company offering access to health-and-wellness treatments through its digital platform. Its disclosures include operating and financial results, shareholder letters, material-event reports and clinical or regulatory updates related to products and services available through the platform, including weight loss care.
Proxy and 8-K filings cover board elections, executive compensation, shareholder voting matters, governance practices and capital-structure disclosures. The filing record also documents Class A common stock matters, share repurchase authorizations, material agreements, Regulation FD disclosures and other events affecting the company’s public-company reporting obligations.
Hims & Hers Health, Inc. director David B. Wells reported an open-market purchase of Class A Common Stock. On May 26, 2026, he bought 48,400 shares at an average price of $24.235 per share, increasing his direct holdings to 224,417 shares.
The reported purchase price is a weighted average, with individual trades executed between $24.19 and $24.25 per share. Wells conducted these transactions as direct ownership in the company’s Class A Common Stock.
Hims & Hers Health, Inc. director and Chief Medical Officer Patrick Harrison received a grant of 435 Restricted Stock Units as part of his board compensation. The RSUs were issued in lieu of a $10,000 cash retainer for the first quarter of 2026 and convert into Class A Common Stock on vesting. The award will vest in full on the company’s next quarterly vesting date, giving him equity-based compensation instead of cash for that period.
Payne Christopher D reported acquisition or exercise transactions in this Form 4 filing.
Hims & Hers Health, Inc. director Christopher D. Payne received a grant of 647 Restricted Stock Units as equity compensation. Each RSU represents a contingent right to receive one share of Class A common stock. The award was issued under the company’s Director Compensation Policy.
The RSUs were granted in lieu of $14,875 in director and committee cash fees for the first quarter of 2026, using a grant price of $22.98. All 647 RSUs will vest in full on the company’s next quarterly vesting date, leaving Payne with 647 RSUs reported as directly owned after this transaction.
WELLS DAVID B reported acquisition or exercise transactions in this Form 4 filing.
Hims & Hers Health, Inc. director David B. Wells received a grant of 957 restricted stock units as part of his 2026 first-quarter board compensation. The RSUs were issued in lieu of $22,000 of cash retainer and committee fees, using a grant price of $22.98 per unit. Each RSU represents a contingent right to receive one share of Class A common stock and will vest in full on the company’s next quarterly vesting date. Following this compensation grant, Wells holds 957 RSUs directly.
Hims & Hers Health, Inc. issued $402.5 million principal amount of 0.00% Convertible Senior Notes due 2032 in a private offering to qualified institutional buyers. The notes pay no regular interest, mature on June 1, 2032, and can be converted into cash, Class A common stock, or a combination.
The initial conversion rate is 33.8590 shares per $1,000 principal amount, implying an initial conversion price of about $29.53 per share. A maximum of 18,057,397 shares may be issued on conversion under the initial maximum conversion rate, subject to customary anti‑dilution adjustments.
The company also entered into capped call transactions covering the shares underlying the notes, with an initial cap price of approximately $50.15 per share and a cost of about $36.7 million. These capped calls are designed to reduce potential dilution or offset cash payments above principal upon conversion, subject to the cap.
Hims & Hers Health, Inc. issued $402.5 million principal amount of 0.00% Convertible Senior Notes due 2032 in a private offering to qualified institutional buyers. The notes pay no regular interest, mature on June 1, 2032, and can be converted into cash, Class A common stock, or a combination.
The initial conversion rate is 33.8590 shares per $1,000 principal amount, implying an initial conversion price of about $29.53 per share. A maximum of 18,057,397 shares may be issued on conversion under the initial maximum conversion rate, subject to customary anti‑dilution adjustments.
The company also entered into capped call transactions covering the shares underlying the notes, with an initial cap price of approximately $50.15 per share and a cost of about $36.7 million. These capped calls are designed to reduce potential dilution or offset cash payments above principal upon conversion, subject to the cap.
Hims & Hers Health, Inc. Chief Financial Officer Oluyemi Okupe reported an option exercise and related share sale in Class A common stock. He exercised stock options to acquire 7,950 shares at $5.01 per share and sold 7,950 shares at an average price of $23.6372 per share.
Following these transactions, he held 262,954 shares directly and 7,853 shares indirectly through the Oluyemi Okupe Separate Property Trust dated September 1, 2021. The filing notes that the stock option exercises and sales were effected under a Rule 10b5-1 trading plan adopted on May 21, 2025, and that the stock options were fully vested and exercisable.
Hims & Hers Health, Inc. is raising capital through a private offering of 0.00% convertible senior notes due 2032. The company priced $350 million in aggregate principal amount, upsized from a proposed $300 million, with an option for an additional $52.5 million.
Hims & Hers expects net proceeds of about $338.5 million, to support international expansion, including its proposed Eucalyptus acquisition, and to invest in technology, fulfillment infrastructure, and AI-driven platform capabilities. A portion, including approximately $32.0 million, will fund capped call transactions intended to limit dilution from note conversions.
Hims & Hers Health, Inc. Schedule 13G discloses beneficial ownership by four affiliated broker-dealer entities reporting collective shared voting and dispositive power over 14,502,395 shares, representing 6.5% of the Class A common stock as of March 31, 2026.
The filing states that Susquehanna Investment Group reports options to buy 560,500 shares and Susquehanna Securities, LLC reports options to buy 12,290,400 shares. The issuer had 222,326,117 shares outstanding as of March 31, 2026 per the company's Form 10-Q filed May 11, 2026.
Hims & Hers Health, Inc. Schedule 13G/A amendment reports that Capital World Investors is beneficially owned of 2 shares of Common Stock, representing 0.0% of the 219,561,143 shares believed to be outstanding. The filing is signed by an authorized representative on 05/13/2026.
Hims & Hers Health reported Q1 2026 revenue of $608.1 million, up from $586.0 million a year earlier, but shifted from profit to a net loss of $92.1 million, or $(0.40) per diluted share, versus diluted EPS of $0.20 in Q1 2025.
Results were pressured by $33.5 million in non-recurring restructuring and related charges tied to a U.S. weight-loss offering shift and $17.6 million of fair value losses on liabilities plus $9.7 million on equity securities. The company still generated $89.4 million in operating cash flow and ended the quarter with $222.3 million in cash and $528.6 million in short-term investments.
Hims & Hers closed the $153.0 million YourBio acquisition, continued integrating prior Medici and Zava deals, and outlined a planned Eucalyptus purchase for up to $1.15 billion. It also carried $1.0 billion of 0% convertible notes due 2030 and recorded a $15.0 million accrual related to an FTC ROSCA investigation.